Item

HSD3B1 and overall survival (OS) in high-risk non-metastatic (M0) and metastatic (M1) prostate cancer starting androgen deprivation therapy (ADT) in the enzalutamide (ENZ) and abiraterone acetate plus prednisolone (AAP) STAMPEDE phase 3 trial

Sharifi, N.
; 
Kayani, M.
; 
Murphy, L.
; 
Diaz, R.
; 
Grist, E.
; 
Kote-Jarai, Z.
; 
Eeles, R. A.
; 
Leone, G.
; 
Clarke, N. W.
; 
Parmar, M. K. B.
... show 3 more
Citations
Google Scholar:
Lookup
Altmetric:
Abstract
Authors
Sharifi, N.
Kayani, M.
Murphy, L.
Diaz, R.
Grist, E.
Kote-Jarai, Z.
Eeles, R. A.
Leone, G.
Clarke, N. W.
Parmar, M. K. B.
Brown, L. C.
James, N. D.
Attard, G.
Affiliation
Univ Miami, Sylvester Comprehens Canc Ctr, Desai Sethi Urol Inst, Miami, FL USA UCL, Canc Inst, London, England Med Res Council Clin Trials Unit, London, England UCL, London, England Inst Canc Res, Oncogenet, London, England Inst Canc Res, Sutton, England Christie & Salford Royal NHS Fdn Trusts, Manchester, England Univ Coll London UCL, MRC Med Res Council Clin Trials Unit, London, England Royal Marsden Hosp NHS Fdn Trust, Inst Canc Res, London, England
Description
Date
2025
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Sharifi N, Kayani M, Murphy L, Diaz R, Grist E, Kote-Jarai Z, et al. HSD3B1 and overall survival (OS) in high-risk non-metastatic (M0) and metastatic (M1) prostate cancer starting androgen deprivation therapy (ADT) in the enzalutamide (ENZ) and abiraterone acetate plus prednisolone (AAP) STAMPEDE phase 3 trial. JOURNAL OF CLINICAL ONCOLOGY. 2025 FEB 10;43(5_SUPPL):234-. PubMed PMID: WOS:001454810300004. English.
Journal Title
Journal ISSN
Volume Title
URI
https://christie.openrepository.com/handle/10541/627792
Embedded videos